Elevated high-sensitivity cardiac troponin is associated with hypertrophy and fibrosis assessed with CMR in patients with hypertrophic cardiomyopathy

Abstract

Background High-sensitivity (hs) cardiac troponin is a valuable biomarker of myocardial injury and frequently elevated in patients with hypertrophic cardiomyopathy (HCM). Using cardiovascular magnetic resonance (CMR) the HCM phenotype can be characterized in great detail with fibrosis as a key finding with prognostic impact. Therefore, our aim was to investigate whether elevated troponin levels in patients with clinical HCM were associated with LV hypertrophy and fibrosis as assessed with CMR. Methods In 62 clinical HCM patients (58% males, mean age 51 ± 15 years) hs-troponin T was determined with a highsensitivity assay (Roche Diagnostics). The lower detection limit is 0.003 pg/l and an elevated hs-troponin is defined as a concentration ≥ the 99 th percentile reference limit (≥ 0.014 pg/l). CMR with late gadolinium enhancement (LGE) was performed (Philips Achieva 1.5T) to assess LV mass indexed to body surface area, maximal wall thickness (MWT) and fibrosis. LV mass, MWT and the presence and extent of LGE were assessed (QMass 7.0, Medis) and compared between HCM patients with and without an elevated hs-troponin using Mann Whitney U or Fisher exact testing. Results Hs-troponin was detectable in 46 HCM patients (74%), of whom 16 patients had an elevated hs-troponin level. The median LV mass and MWT were higher in HCM patients with an elevated hs-troponin (p<0.001). The difference in the presence of fibrosis was almost statistically significant between groups. Notably, if present, the extent of fibrosis was higher in patients with an elevated hs-troponin (p= 0.04) (Table 1).